Dan You,Stephen Hillerman,Gregory Locke,Charu Chaudhry,Caitlyn Stromko,Anwar Murtaza,Yi Fan,Jennifer Koenitzer,Yali Chen,Stephanie Briceno,Rajarshi Bhadra,Elizabeth Duperret,Johnni Gullo-Brown,Chan Gao,Dandan Zhao,John Feder,Joshua Curtin,Andrew P Degnan,Godwin Kumi,Mark Wittman,Benjamin M Johnson,Karen E Parrish,Giridharan Gokulrangan,John Morrison,Michael Quigley,John T Hunt,Luisa Salter-Cid,Emma Lees,Miguel A Sanjuan,Jinqi Liu

Abstract:Background Hematopoietic progenitor kinase 1 (HPK1 or MAP4K1) has been demonstrated as a negative intracellular immune checkpoint in mediating antitumor immunity in studies with HPK1 knockout and kinase dead mice. Pharmacological inhibition of HPK1 is desirable to investigate the role of HPK1 in human immune cells with therapeutic implications. However, a significant challenge remains to identify a small molecule inhibitor of HPK1 with sufficient potency, selectivity, and other drug-like properties suitable for proof-of-concept studies. In this report, we identified a novel, potent, and selective HPK1 small molecule kinase inhibitor, compound K (CompK). A series of studies were conducted to investigate the mechanism of action of CompK, aiming to understand its potential application in cancer immunotherapy. Methods Human primary T cells and dendritic cells (DCs) were investigated with CompK treatment under conditions relevant to tumor microenvironment (TME). Syngeneic tumor models were used to assess the in vivo pharmacology of CompK followed by human tumor interrogation ex vivo. Results CompK treatment demonstrated markedly enhanced human T-cell immune responses under immunosuppressive conditions relevant to the TME and an increased avidity of the T-cell receptor (TCR) to recognize viral and tumor-associated antigens (TAAs) in significant synergy with anti-PD1. Animal model studies, including 1956 sarcoma and MC38 syngeneic models, revealed improved immune responses and superb antitumor efficacy in combination of CompK with anti-PD-1. An elevated immune response induced by CompK was observed with fresh tumor samples from multiple patients with colorectal carcinoma, suggesting a mechanistic translation from mouse model to human disease. Conclusion CompK treatment significantly improved human T-cell functions, with enhanced TCR avidity to recognize TAAs and tumor cytolytic activity by CD8+ T cells. Additional benefits include DC maturation and priming facilitation in tumor draining lymph node. CompK represents a novel pharmacological agent to address cancer treatment resistance.

An Updated Review of Small-Molecule HPK1 Kinase Inhibitors (2016-Present)

Opportunities and challenges for targeting HPK1 in cancer immunotherapy

Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress

Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues As Novel HPK1 Inhibitors

Discovery of Potent and selective HPK1 Inhibitors Based on the 2,4-disubstituted Pyrimidine Scaffold with Immune Modulatory properties for Ameliorating T cell exhaustion

Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies

Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues As New HPK1 Inhibitors.

Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1

Recent advances in hematopoietic cell kinase in cancer progression: Mechanisms and inhibitors

Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1

Discovery of 1(2H)-phthalazinone and 1(2H)-isoquinolinone derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy

Discovery of Pyridine-2-Carboxamides Derivatives As Potent and Selective HPK1 Inhibitors for the Treatment of Cancer.

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications

Review on the Research Development of Small Molecular Protein Tyrosine Kinases Inhibitors